DiaMedica Therapeutics Inc. Common Stock (DMAC)
Stock · NASDAQ · Health Care
$6.39as of 8/28/2026
Price chart
Open in TradingViewActive signals
Resistance level
$6.66
Industry
Biotechnology: Pharmaceutical Preparations
About DMAC
DiaMedica Therapeutics Inc., a clinical stage biopharmaceutical company, focuses on improving the lives of people suffering from severe ischemic diseases. Its lead candidate is DM199, a pharmaceutically active recombinant form of the human tissue kallikrein-1 protein, which is in Phase 2/3 trials for the treatment of acute ischemic stroke, as well as in Phase 2 to treat preeclampsia, cardio renal disease, and fetal g…
- Sector
- Health Care
- Industry
- Biotechnology: Pharmaceutical Preparations
- Employees
- 35
- Website
- www.diamedica.com/
Fundamentals
- 1-day range
- $6.69$6.94
- Market cap
- $364.79M
- P/E (trailing)
- —
- P/E (forward)
- -7.67
- EPS (trailing)
- $-0.71
- Dividend yield
- —
- Beta
- 0.97
- Avg. volume
- 199.7K
- Dividend pay date
- November 15, 2018
52-week range
$5.14$10.42
Next earnings: August 10, 2026 · EPS estimate $-0.20After Closeconfirmed
How DiaMedica Therapeutics Inc. Common Stock Makes Money
Where the revenue actually goes — FY2018 annual results
Source: 10-K filed Mar 19, 2019 · via SEC EDGAR / Finnhub
Forecasts
4 analyst ratings
Buy 91%
Hold 9%
Sell 0%
1-year price forecast
High
$25
+291.2%
Median
$13
+103.4%
Low
$11
+72.1%
DiaMedica Therapeutics Inc. Common Stock Competitors
Chosen by industry and closest market cap.
- DMACDiaMedica Therapeutics Inc. Common Stock$6.39▼ 5.33%Market cap $364.79MP/E —$5.14$10.42
- ZNTLZentalis Pharmaceuticals Inc. Common Stock$3.8▼ 2.06%Market cap $355.93MP/E —$1.21$6.95
- UPBUpstream Bio Inc. Common Stock$6.68▼ 1.62%Market cap $373.87MP/E —$5.85$33.68
- RCKTRocket Pharmaceuticals Inc. Common Stock$3.86▲ 6.49%Market cap $386.55MP/E —$2.53$5.45
- ENTAEnanta Pharmaceuticals Inc. Common Stock$13.6▼ 1.45%Market cap $387.91MP/E —$7.05$17.15
- CATXPerspective Therapeutics Inc. Common Stock$3.1▼ 2.67%Market cap $338.72MP/E —$1.96$6.16
- FHTXFoghorn Therapeutics Inc. Common Stock$6▼ 3.54%Market cap $327.04MP/E —$3.27$7.61
| Symbol | Market cap | P/E ratio | Price | 1D | 52-week range |
|---|---|---|---|---|---|
| DMAC DiaMedica Therapeutics Inc. Common Stock | $364.79M | — | $6.39 | ▼ 5.33% | $5.14$10.42 |
| ZNTL Zentalis Pharmaceuticals Inc. Common Stock | $355.93M | — | $3.8 | ▼ 2.06% | $1.21$6.95 |
| UPB Upstream Bio Inc. Common Stock | $373.87M | — | $6.68 | ▼ 1.62% | $5.85$33.68 |
| RCKT Rocket Pharmaceuticals Inc. Common Stock | $386.55M | — | $3.86 | ▲ 6.49% | $2.53$5.45 |
| ENTA Enanta Pharmaceuticals Inc. Common Stock | $387.91M | — | $13.6 | ▼ 1.45% | $7.05$17.15 |
| CATX Perspective Therapeutics Inc. Common Stock | $338.72M | — | $3.1 | ▼ 2.67% | $1.96$6.16 |
| FHTX Foghorn Therapeutics Inc. Common Stock | $327.04M | — | $6 | ▼ 3.54% | $3.27$7.61 |
P/E shows — for peers not currently carrying a live signal of their own.
Latest news
- DiaMedica (DMAC) Q2 2026 Earnings Call TranscriptYahoo · 8/18/2026
- All You Need to Know About DiaMedica Therapeutics (DMAC) Rating Upgrade to BuyYahoo · 8/13/2026
- DiaMedica Therapeutics Inc (DMAC) (Q2 2026) Earnings Call Highlights: Promising Preeclampsia ...Yahoo · 8/11/2026
- DiaMedica Therapeutics Inc. Q2 2026 Earnings Call SummaryYahoo · 8/11/2026
- HC Wainwright & Co. Reiterates Buy on DiaMedica Therapeutics, Maintains $12 Price Targetbenzinga · 8/11/2026
- DiaMedica Therapeutics Q2 Earnings Call HighlightsYahoo · 8/11/2026
- DiaMedica Therapeutics Inc. (DMAC) Q2 2026 Earnings Call TranscriptSeekingAlpha · 8/11/2026
- HC Wainwright & Co. Reiterates Buy on DiaMedica Therapeutics, Maintains $12 Price TargetBenzinga · 8/11/2026
- DiaMedica Therapeutics Reports Second Quarter 2026 Financial Results and Provides Business HighlightsYahoo · 8/10/2026
Insider Activity
Insider Actions →Acquired
922.9K
Disposed
0
- Dietrich John Pauls · August 10, 2026 · Grant60.2K
- Charles Pauling Semba · June 1, 2026 · Grant40.4K
- Dietrich John Pauls · June 1, 2026 · Grant380.0K
- James T. Parsons · June 1, 2026 · Grant51.2K
- Randall Michael Giuffre · June 1, 2026 · Grant40.4K
- Julie Krop · June 1, 2026 · Grant67.5K
- Kellen Scott · June 1, 2026 · Grant162.0K
- Lewis Tanya · June 1, 2026 · Grant40.4K
- O'Connor Daniel J. · June 1, 2026 · Grant40.4K
- Richard Kuntz · June 1, 2026 · Grant40.4K
Institutional Ownership
March 31, 2026
- Total shares held
- 11.26M
- Total value held
- $75.63M
- Institutional holders
- 93
Top holders this quarter
- Unknown2.02M
- Unknown1.86M
- Unknown935.6K
- Unknown875.0K
- Unknown780.5K
- Unknown644.2K
- Unknown455.0K
- Unknown382.3K
- Unknown338.5K
- Unknown333.5K
See the full, filterable feed with live charts on the MarketWall dashboard.